Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Aim(s): This study aims to evaluate the efficacy and safety of the anti-PD-L1 antibody Avelumab in patients (pts) with NEN G3 progressing after first-line chemotherapy.
Materials and methods: In a multicenter, national, single-arm, open-label, phase II trial the efficacy and safety of Avelumab was evaluated in patients with metastatic progressive Neuroendocrine Carcinomas (NEC G3) according to WHO 2010, excluding Merkel cell carcinoma and small cell lung cancer.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
To read results and conclusion, please login ...
Further abstracts you may be interested in